A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters

The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fagre, Anna C., Manhard, John, Adams, Rachel, Eckley, Miles, Zhan, Shijun, Lewis, Juliette, Rocha, Savannah M., Woods, Catherine, Kuo, Karina, Liao, Wuxiang, Li, Lin, Corper, Adam, Challa, Dilip, Mount, Emily, Tumanut, Christine, Tjalkens, Ronald B., Aboellail, Tawfik, Fan, Xiaomin, Schountz, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775388/
https://www.ncbi.nlm.nih.gov/pubmed/33391285
http://dx.doi.org/10.3389/fimmu.2020.614256

Ejemplares similares

Ejemplares similares